|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 100 DAINGERFIELD ROAD |
Address2 | 3rd FLOOR |
City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 27478-12
|
||||||||
|
6. House ID# 303540000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Anne Cassity |
Date | 1/21/2024 8:51:29 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
H.R. 501, the Block, Report, and Suspend Suspicious Shipments Act;
S. 2666, the E-Prescribing Parity for Controlled Substances Act
Remote Prescribing of Controlled Substances
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act;
S. 2052, the Protect Patient Access to Pharmacies Act;
H.R. 2880, the Protecting Patients Against PBM Abuses Act;
H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act;
S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act;
H.R. 2816, the PBM Sunshine and Accountability Act;
H.R. 3281, the Transparent PRICE Act;
H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act;
H.R. 3561, the PATIENT Act;
S. 1967, the Patients Before Middlemen (PBM) Act;
S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act;
S. 2405, the Strengthening Pharmacy Access for Seniors Act;
S. 2973, the Modernizing and Ensuring PBM Accountability Act;
H.R. 5378, the Lower Costs, More Transparency Act;
H.R.5385, the Medicare PBM Accountability Act;
H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes;
H.R. 5400 / S. 2436, the NO PBMs Act;
S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023;
Request for Information Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act (IRA; P.L. 117-169)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Small Business Administration (SBA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023;
H.R. 382, the Pandemic is Over Act;
H.R. 2679, the Pharmacy Benefits Manager Accountability Act;
H.R. 3008, the Drug Shortage Prevention Act;
S. 1339, the Pharmacy Benefits Manager Reform Act;
S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act;
H.R. 5142, the Vaccine Injury Compensation Modernization Act of 2023;
H.R. 5143, the Vaccine Access Improvement Act of 2023;
S. 2305, the Biosimilar Red Tape Elimination Act;
H.R. 1173, the Patients Right to Know Their Medication Act of 2023;
Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959);
Implementation of Public Law 113-54, the Drug Quality and Security Act;
Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517);
H.R. 5400 / S. 2436, the NO PBMs Act;
S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S. 1108, the Death Tax Repeal Act;
H.R. 4794, the Dietary Supplement Access Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phillip |
Harbison |
|
|
|
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
S. 127, the PBM Transparency Act;
S. 113, the Prescription Pricing for the People Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Phillip |
Harbison |
|
|
|
Matthew |
Seiler |
|
|
|
Kaitlin |
Krell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
TRICARE pharmacy network changes;
H.R. 2670, the Military Construction Authorization Act for Fiscal Year 2024;
H.R. 2670, National Defense Authorization Act for Fiscal Year 2024;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Phillip |
Harbison |
|
|
|
Kaitlin |
Krell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY24 appropriations language request to fund FTC enforcement of the Robinson-Patman Act;
FY24 appropriations report language to address pharmacy compounding;
FY24 appropriations report language to address TRICARE pharmacy network;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phillip |
Harbison |
|
|
|
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
H.R.4035 / S. 2623, the Protecting Small Business Information Act of 2023
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phillip |
Harbison |
|
|
|
Kaitlin |
Krell |
|
|
|
Anne |
Cassity |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |